Drugs / Liothyronine
Liothyronine
also known as
triiodothyronine · liothyronine sodium · L-T3 · T3 · Cytomel · Triostat · 3,5,3'-triiodothyronine, l- · Basoprocin · +38 more
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | CYTOMEL | — | 1956-05-08 | fda.gov ↗ |
Trials 41 · a red edge is where a trial was stopped
1955195619571958195919601961196219631964196519661967196819691970197119721973197419751976197719781979198019811982198319841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027202820292030203120322033
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05017610 | Oct 2021 → Oct 2022 | gliosarcoma | Emory University | Withdrawn | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT02506751 | Jul 2015 → Sep 2017 | primary progressive multiple sclerosis, relapsing-remitting multiple sclerosis, secondary progressive multiple sclerosis | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1 | NCT00289367 | Feb → Aug 2006 | atrial fibrillation | Northwell Health | Completed | No outcome recorded |
| Phase 1 | NCT00004828 | Dec 1994 → Dec 1997 | tricuspid atresia | FDA Office of Orphan Products Development | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07346157 | Jul 2026 → Mar 2031 expected | childhood medulloblastoma | Sabine Mueller, MD, PhD | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT05384847 | Dec 2022 → May 2026 overdue | heart failure | Emory University | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03098433 | Oct 2017 → Jun 2019 | — | Virginia Commonwealth University | Completed | No outcome recorded |
| Phase 212 trials | ||||||
| Phase 2 | NCT07424183 | Jun 2026 → Jun 2027 expected | hypothyroidism | University of Pennsylvania | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT04725110 | Jan 2026 → Oct 2030 | COVID-19, acute respiratory distress syndrome | University of Minnesota | Withdrawn | No outcome recorded |
| Phase 2 | NCT05270798 | May 2022 → Aug 2023 | euthyroid sick syndrome, infectious disease with sepsis | Cantonal Hospital Zenica | Completed | No outcome recorded |
| Phase 2 | NCT04782856 | Oct 2020 → Apr 2023 | goiter, hypothyroidism, thyroid cancer | Virginia Commonwealth University | Completed | No outcome recorded |
| Phase 2 | NCT04348513 | May 2020 → Apr 2021 | COVID-19 | Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. | Terminated | No outcome recorded |
| Phase 2 | NCT04115514 | Mar 2020 → Oct 2026 expected | acute respiratory distress syndrome, pulmonary edema, thyroid gland disorder | University of Minnesota | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03787303 | Mar 2019 → Mar 2022 | breast cancer, thyroid gland disorder | Aultman Health Foundation | Terminated | No outcome recorded |
| Phase 2 | NCT03627611 | Aug 2018 → Jun 2020 | hypothyroidism | Oslo University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT02654041 | Mar 2016 → Jun 2017 | glioblastoma | Musli Thyropeutics Ltd. | Terminated | No outcome recorded |
| Phase 2 | NCT02457897 | Apr 2015 → Sep 2018 | diabetes mellitus | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 2 | NCT01800617 | Mar 2013 → Jul 2014 | hypothyroidism | Ipe, LLC | Completed | No outcome recorded |
| Phase 2 | NCT01780584 | Apr → Sep 2010 | euthyroid sick syndrome | National Cardiovascular Center Harapan Kita Hospital Indonesia | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT06731764 | Dec 2024 → Dec 2027 expected | hypothyroidism | UConn Health | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03053115 | Mar 2017 → Sep 2021 | hypothyroidism | Azienda USL Modena | Completed | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT02320669 | Nov 2014 → Oct 2019 | congenital heart defects, multiple types | Seattle Children's Hospital | Completed | No outcome recorded |
| Phase 3 | NCT02521168 | Jul 2013 → Oct 2014 | postoperative ventricular dysfunction | National Cardiovascular Center Harapan Kita Hospital Indonesia | Completed | No outcome recorded |
| Phase 3 | NCT00790738 | Jul 2008 → Jul 2012 | bipolar disorder, depressive disorder | Northwell Health | Completed | No outcome recorded |
| Phase 3 | NCT00158990 | Oct 2002 → Jul 2007 | bipolar disorder, major depressive disorder | Hadassah Medical Organization | Completed | No outcome recorded |
| Phase 3 | NCT00073242 | Jul 2000 → Jul 2015 | obesity disorder | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Unknown | No outcome recorded |
| Phase 46 trials | ||||||
| Phase 4 | NCT05247476 | Oct 2021 → Mar 2022 | postsurgical hypothyroidism, thyroid gland papillary carcinoma | Zhongshan Hospital Xiamen University | Unknown | No outcome recorded |
| Phase 4 | NCT00360074 | Feb 2004 → Apr 2007 | hyperlipidemia, hypopituitarism, thyroid gland disorder | University Hospital Freiburg | Completed | No outcome recorded |
| Phase 4 | NCT00221494 | Jan 2004 → Jun 2006 | depressive disorder | Mark Frye | Withdrawn | No outcome recorded |
| Phase 4 | NCT00296686 | Sep 2001 → Aug 2006 | major depressive disorder | New York State Psychiatric Institute | Terminated | No outcome recorded |
| Phase 4 | NCT00021528 | Jul 2001 → Sep 2006 | major depressive disorder | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 4 | NCT00208702 | Sep 1996 → Jul 2003 | major depressive disorder | Emory University | Completed | No outcome recorded |
| Phase not applicable9 trials | ||||||
| — | NCT02399475 | Jan 2015 → Sep 2019 | hypothyroidism | University of Pennsylvania | Completed | No outcome recorded |
| — | NCT01481402 | Jul 2011 → Feb 2014 | euthyroid sick syndrome, heart failure | Jens Faber | Completed | No outcome recorded |
| — | NCT01360177 | Jul 2010 → Dec 2013 | breast cancer | Stanford University | Withdrawn | No outcome recorded |
| — | NCT01153360 | Jun 2010 → Aug 2011 | euthyroid sick syndrome | Yonsei University | Completed | No outcome recorded |
| — | NCT00903877 | May 2009 → Jun 2011 | fibromyalgia | Stanford University | Completed | No outcome recorded |
| — | NCT00421369 | Sep 2007 → Aug 2011 | major depressive disorder | Hadassah Medical Organization | Completed | No outcome recorded |
| — | NCT00488644 | Feb 2006 → Mar 2010 | brain neoplasm, hypothyroidism | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| — | NCT00223158 | Sep 2003 → May 2005 | thyroid cancer | Patrice Perron | Completed | No outcome recorded |
| — | NCT00562367 | Oct 2001 → Sep 2004 | major depressive disorder | Massachusetts General Hospital | Completed | No outcome recorded |
Also used as a comparator or background therapy in 17 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT02760056 Comparator | Jun 2016 → Jan 2017 | multiple sclerosis | Oregon Health and Science University | Completed | No outcome recorded |
| Phase 1 | NCT01581463 Comparator | Apr → Aug 2012 | — | Ipe, LLC | Completed | No outcome recorded |
| Phase 1 | NCT00788307 Background | Nov 2008 → Feb 2018 | prostate cancer | Mayo Clinic | Terminated | No outcome recorded |
| Phase 1 | NCT00978055 Comparator | Oct → Dec 2007 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00004062 Background | Jul 1999 → Aug 2006 | head and neck cancer | Lucille P. Markey Cancer Center at University of Kentucky | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04111536 Comparator | Mar 2020 → Oct 2023 | diastolic heart failure, euthyroid sick syndrome | University of Pennsylvania | Completed | No outcome recorded |
| Phase 1/2 | NCT04112316 Comparator | Feb 2020 → Oct 2023 | systolic heart failure, thyroid hormone metabolism, abnormal, 3 | University of Pennsylvania | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT04743661 Background | Apr 2022 → Mar 2026 overdue | ependymoma, medulloblastoma | Pediatric Brain Tumor Consortium | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01182285 Comparator | Sep 2010 → Sep 2015 | thyroid cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00106119 Comparator | Mar 2005 → Nov 2013 | thyroid gland disorder | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT05894954 Background | Jul 2023 → Oct 2025 | cognitive impairment with or without cerebellar ataxia, dementia | Alzheimer's Prevention and Reversal Project, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT05682482 Comparator | Oct 2022 → Jan 2028 expected | hypothyroidism | M. Medici | Recruiting | No outcome recorded |
| Phase 3 | NCT00027417 Comparator | Apr 2001 → Aug 2007 | congenital heart disease | Michael Portman | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00531713 Comparator | Apr 2003 → Mar 2007 | depressive disorder | Copenhagen University Hospital at Herlev | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT07568574 Background | Mar 2026 → May 2028 expected | — | Enhanced Emirates Limited | Enrolling by invitation | No outcome recorded |
| — | NCT02317926 Comparator | May 2015 → May 2018 | hypothyroidism | Walter Reed National Military Medical Center | Unknown | No outcome recorded |
| — | NCT00715572 Comparator | Mar 2002 → Feb 2004 | hypothyroidism | I.M. Sechenov First Moscow State Medical University | Completed | No outcome recorded |
Evidence & citations 51 cited values
Every value below carries the sentence it was read from. 64 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | liothyronine | “The study goals are: 1.) To assess whether the simultaneous commencement of liothyronine or pindolol to an SSRI can accelerate the treatment response (i.e. faster rate of...” NCT00221494 ↗29“Atrophic subtype support may include: estradiol, progesterone, testosterone, DHEA, pregnenolone, levothyroxine, liothyronine, hydrocortisone.” NCT05894954 ↗ |
| Known as | 3,5,3'-triiodothyronine, l- | ChEMBL registry synonym — accepted as the source's own label CHEMBL1544 ↗ |
| Known as | Basoprocin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1544 ↗ |
| Known as | BCT303 | “This preparation of T3 is called Thyromax® or BCT303.” NCT01800617 ↗ |
| Known as | Cynomel | ChEMBL registry synonym — accepted as the source's own label CHEMBL1544 ↗ |
| Known as | Cyronine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1544 ↗ |
| Known as | Cytobin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1544 ↗ |
| Known as | Cytomel | “Cytomel (liothyronine) 25-50 mcg/day for 4 weeks” NCT00562367 ↗ |
| Known as | cytomel (liothyronine) | “cytomel (liothyronine)” NCT00790738 ↗ |
| Known as | Euthroid-0.5 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1544 ↗ |
| Known as | Euthroid-1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1544 ↗ |
| Known as | Euthroid-2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1544 ↗ |
| Known as | Euthroid-3 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1544 ↗ |
| Known as | Ibiothyron | ChEMBL registry synonym — accepted as the source's own label CHEMBL1544 ↗ |
| Known as | L-3,5,3'-triiodothyronine | “Thyroid hormones play multiple roles in lung function, and L-3,5,3'-triiodothyronine (T3) has multiple effects on lung alveolar type II cells.” PMID 33127750 ↗ Oct 2020 |
| Known as | L-T3 | “A recent trial showed that 1:3 μg:μg liothyronine (L-T3) substitution for levothyroxine (L-T4) achieving near-identical TSH levels resulted in a significant decrease in weight...” PMID 23585666 ↗ Apr 20136“Liothyronine (L-T3) is a short-acting thyroid hormone with demonstrated safety and tolerability for short-term and chronic use in euthyroid adults with other health conditions,...” PMID 32120028 ↗ Feb 2020 “The effects of levothyroxine (LT4)/liothyronine (LT3) combination therapy on quality of life (QoL) in hypothyroid patients former on LT4 monotherapy have been disappointing.” PMID 35273566 ↗ Feb 2022 “Liothyronine (L-triiodothyronine or LT3) in the 5 mcg tablet dose formulation.” NCT04111536 ↗ “Liothyronine/levothyroxine (LT3/LT4) combination therapy.” NCT04782856 ↗ “liothyronine (synthetic T3, LT3)” NCT06731764 ↗ “Liothyronine (L-T3)” NCT07424183 ↗ |
| Known as | L-triiodothyronine | “Liothyronine (L-triiodothyronine or LT3) in the 5 mcg tablet dose formulation.” NCT04112316 ↗ |
| Known as | L-triiodothyronine hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL1544 ↗ |
| Known as | L-triiodothyronine sodium salt | ChEMBL registry synonym — accepted as the source's own label CHEMBL1544 ↗ |
| Known as | Levothyroxine sodium related compound liothyronine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1544 ↗ |
| Known as | Liothyronine hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL1544 ↗ |
| Known as | liothyronine sodium | “The safety of a commercially available formulation of liothyronine sodium (synthetic T3) administered intratracheally was assessed in an Investigational New Drug...” PMID 33127750 ↗ Oct 20207“bolus administration of Liothyronine Sodium/Triiodothyronine (Triostat) immediately prior to CPB institution and after removal of aortic cross clamp, followed by repeated boluses” NCT00027417 ↗ “Participants will have their L-thyroxine (T4) discontinued and Triiodothyronine (T3)/liothyronine sodium initiated at 3: 1 and titrated.” NCT03787303 ↗ “liothyronine sodium (triiodothyronine)” PMID 17548749 ↗ Jun 2007 |
| Known as | Liothyronine sodium salt | ChEMBL registry synonym — accepted as the source's own label CHEMBL1544 ↗ |
| Known as | Liotironina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1544 ↗ |
| Known as | Liotrix (t3) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1544 ↗ |
| Known as | Lyothyronin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1544 ↗ |
| Known as | NSC-758175 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1544 ↗ |
| Known as | NSC-80203 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1544 ↗ |
| Known as | NSC-80774 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1544 ↗ |
| Known as | T3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00073242 ↗ |
| Known as | T3 (liotrix) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1544 ↗ |
| Known as | T3 sodium salt | ChEMBL registry synonym — accepted as the source's own label CHEMBL1544 ↗ |
| Known as | Tertroxin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1544 ↗ |
| Known as | Thybon | ChEMBL registry synonym — accepted as the source's own label CHEMBL1544 ↗ |
| Known as | Thyrolar-0.25 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1544 ↗ |
| Known as | Thyrolar-0.5 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1544 ↗ |
| Known as | Thyrolar-1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1544 ↗ |
| Known as | Thyrolar-2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1544 ↗ |
| Known as | Thyrolar-3 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1544 ↗ |
| Known as | Thyrolar-5 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1544 ↗ |
| Known as | Thyromax | “This preparation of T3 is called Thyromax® or BCT303.” NCT01800617 ↗ |
| Known as | triiodothyronine | “acute administration of triiodothyronine (T3) in critically ill COVID-19 infected patients requiring mechanical respiratory support or Extra Corporeal Membrane Oxygenation (ECMO).” PMID 32586399 ↗ Jun 202016“Thyroid hormone replacement for central hypothyroidism: a randomized controlled trial comparing two doses of thyroxine (T4) with a combination of T4 and triiodothyronine.” PMID 17711927 ↗ Aug 2007 “Sequential Tranylcypromine (TC), TC + Dextroamphetamine and TC + Triiodothyronine for Refractory Depression” NCT00296686 ↗ “Oral Triiodothyronine Normalizes T3 Levels After Surgery For Pediatric Congenital Heart Disease” NCT01780584 ↗ “transient triiodothyronine (thyroid hormone T3) administration in patients with HF” NCT05384847 ↗ “T3 (Triiodothyronine)” NCT00021528 ↗ |
| Known as | Triiodothyronine (t3 or liothyronine, active) (6-11%) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1544 ↗ |
| Known as | Triiodothyronine (T3) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03787303 ↗ |
| Known as | Triiodothyronine sodium salt | ChEMBL registry synonym — accepted as the source's own label CHEMBL1544 ↗ |
| Known as | Triiodothyronine,evans | ChEMBL registry synonym — accepted as the source's own label CHEMBL1544 ↗ |
| Known as | Triostat | “bolus administration of Liothyronine Sodium/Triiodothyronine (Triostat) immediately prior to CPB institution and after removal of aortic cross clamp, followed by repeated boluses” NCT00027417 ↗ |
| Action | Restore | “Repletion of T3 following weight loss induced by dietary modification” NCT00073242 ↗ |
| Modality | Other / unclassified | “a synthetic thyroid hormone” NCT02320669 ↗ |
| Modality | Small molecule | — CHEMBL1544 ↗ |
| Route | Oral | “oral liothyronine sodium twice daily” NCT00004062 ↗ |